Johnson & Johnson (NYSE:JNJ) Position Cut by Red Wave Investments LLC

Red Wave Investments LLC lowered its position in shares of Johnson & Johnson (NYSE:JNJ) by 15.9% in the 4th quarter, Holdings Channel reports. The fund owned 3,182 shares of the company’s stock after selling 600 shares during the period. Red Wave Investments LLC’s holdings in Johnson & Johnson were worth $460,000 as of its most recent filing with the SEC.

Other hedge funds have also recently bought and sold shares of the company. IFS Advisors LLC raised its holdings in shares of Johnson & Johnson by 138.9% during the fourth quarter. IFS Advisors LLC now owns 172 shares of the company’s stock valued at $25,000 after buying an additional 100 shares during the last quarter. Highline Wealth Partners LLC acquired a new stake in Johnson & Johnson in the 3rd quarter valued at approximately $31,000. RPg Family Wealth Advisory LLC bought a new stake in Johnson & Johnson during the 3rd quarter valued at $35,000. Bay Harbor Wealth Management LLC acquired a new position in Johnson & Johnson during the 4th quarter worth $32,000. Finally, Activest Wealth Management acquired a new position in shares of Johnson & Johnson during the third quarter valued at $40,000. 69.55% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the stock. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 25th. Leerink Partners decreased their price objective on shares of Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating for the company in a report on Thursday, January 23rd. Morgan Stanley cut their price objective on Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating for the company in a report on Thursday, January 23rd. Stifel Nicolaus lowered their target price on Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating on the stock in a report on Thursday, January 23rd. Finally, Wolfe Research began coverage on shares of Johnson & Johnson in a research note on Friday, November 15th. They issued an “outperform” rating and a $190.00 price objective on the stock. Nine analysts have rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $170.67.

Insider Activity at Johnson & Johnson

In other news, Director Mark A. Weinberger acquired 1,000 shares of the company’s stock in a transaction that occurred on Thursday, December 12th. The shares were purchased at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the completion of the acquisition, the director now owns 1,000 shares of the company’s stock, valued at approximately $147,220. This represents a ∞ increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Timothy Schmid sold 403 shares of the business’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total transaction of $62,928.45. Following the completion of the sale, the executive vice president now directly owns 15,098 shares of the company’s stock, valued at $2,357,552.70. This represents a 2.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Up 0.9 %

Shares of Johnson & Johnson stock opened at $163.81 on Tuesday. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $168.85. The stock has a 50-day moving average price of $149.33 and a 200 day moving average price of $155.88. The company has a market cap of $394.38 billion, a P/E ratio of 24.63, a P/E/G ratio of 2.56 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, topping the consensus estimate of $1.99 by $0.05. The business had revenue of $22.52 billion during the quarter, compared to analysts’ expectations of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The firm’s quarterly revenue was up 5.3% compared to the same quarter last year. During the same period last year, the company posted $2.29 earnings per share. As a group, analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be issued a dividend of $1.24 per share. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 annualized dividend and a dividend yield of 3.03%. Johnson & Johnson’s dividend payout ratio is 74.59%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.